Skip to main content
Premium Trial:

Request an Annual Quote

Second Chance for 23andMe

The FDA should back off of 23andMe and allow the firm to continue selling its consumer genomics service because it is unlikely to lead to unnecessary diagnostic tests and medical procedures, argues Forbes writer Frida Polli.

Polli takes issue with FDA's recent move to make 23andMe cease marketing its health-related genomics services, saying that the concern that people will go directly from receiving specific genetic information and to rush to expensive and unnecessary tests or procedures is overrated.

"Many steps exist between a woman learning through 23andMe that she has a mutation in one of the BRCA genes linked to breast cancer, and her undergoing a double mastectomy," she writes. "While the 23andMe kit comes in the mail and the results in an email, surgery is hardly undergone with the same ease."

Further, early detection was a main reason for creating the company, Polli says, noting that early detection and prevention may offer savings for the healthcare system.

Polli echoes the sentiments of others, including Misha Angrist, who have argued against FDA's intervention, which some view as overly paternalistic and stifling to new industry.

The big question FDA posed to 23andMe that Polli does not address, however, is whether the test works. If the company is claiming that the genetic information it provides is for use in health, rather than for curiosity or ancestry information, FDA has said it wants to know if the test is valid.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.